# A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer

> **NCT07389733** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shandong Suncadia Medicine Co., Ltd.** · enrollment: 180 (estimated)

## Conditions studied

- Advanced Unresectable or Metastatic Breast Cancer of Adults

## Interventions

- **DRUG:** HRS-6208 Capsule
- **DRUG:** HRS-6209 Capsule
- **DRUG:** HRS-8080 Tablet
- **DRUG:** Fulvestrant injection
- **DRUG:** Letrozole tablets

## Key facts

- **NCT ID:** NCT07389733
- **Lead sponsor:** Shandong Suncadia Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-27
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07389733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07389733, "A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07389733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*